Clinical Trials
40
9 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1902
Active, not recruiting
9
22.5%
Completed
30
75.0%
Unknown
1
2.5%
No approval data available
- The European Union has committed €225 million to advance next-generation flu vaccines through clinical trials, representing the largest EU investment ever dedicated to accelerating innovative medical countermeasures. - This marks the first use of pre-commercial procurement by the European Commission to support vaccine candidates through clinical development, with contracts awarded to 10 organizations for 98-month development programs. - The initiative aims to develop vaccines that protect against broader influenza variants, can be rapidly adapted for pandemic strains, and offer alternative administration methods including nasal sprays, oral doses, and skin patches. - The funding addresses persistent scientific challenges in influenza vaccine development, where a 2025 review found that most critical milestones remain unresolved due to scientific complexity and resource constraints.
- A nationwide Danish cohort study of 1.2 million children found no association between cumulative aluminum exposure from childhood vaccines and 50 chronic health conditions including autoimmune, allergic, and neurodevelopmental disorders. - The research, published in Annals of Internal Medicine, examined children born between 1997-2018 and followed them through 2020, providing robust evidence supporting childhood vaccine safety amid ongoing vaccine skepticism. - For each 1-mg increase in aluminum exposure, adjusted hazard ratios were 0.98 for autoimmune disorders, 0.99 for allergic conditions, and 0.93 for neurodevelopmental disorders, with confidence intervals excluding moderate to large risk increases. - The study addresses concerns about aluminum-containing adjuvants used in routine childhood immunizations including DTaP, Hib, pneumococcal, and hepatitis vaccines to enhance immune response.
